Insmed reported $84.3M in Trade Creditors for its fiscal quarter ending in September of 2026.





Trade Creditors Change Date
BioMarin Pharmaceutical USD 946.11M 32.44M Sep/2026
Cytokinetics USD 25.96M 5.45M Sep/2026
DBV Technologies USD 13.8M 25.7M Sep/2026
Gilead Sciences USD 934M 260M Sep/2026
Heron Therapeutics USD 8.38M 3.27M Sep/2026
Insmed USD 84.3M 9.75M Sep/2026
Novartis USD 4.24B 79M Sep/2026
Regeneron Pharmaceuticals USD 1.14B 19M Sep/2026
Sarepta Therapeutics USD 45.7M 5.28M Sep/2026
Ultragenyx Pharmaceutical USD 45M 6M Sep/2026
Vertex Pharmaceuticals USD 3.71B 99.2M Sep/2026